Skip to content
Head to head

Prestige Consumer Healthcare vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: PBH · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

PBH -15.9%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
PBHTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price49.6321.77
Change today+0.06%+1.68%
1-year return-16.1%+57.5%
Market cap$2.35B$69.76B
52-week range41.77 – 71.0713.92 – 22.07
Valuation
P/E (TTM)15.32311.00
P/E percentile, own 5-yr range39th100th
P/B1.211.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)3.91-0.30
Net profit (TTM)$185.32M$-970.94M
Revenue (TTM)$1.17B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+22.7%+6.7%
Gross margin52.5%65.8%
Operating margin25.0%14.3%
Net margin13.3%0.9%
Free cash flow (TTM)$214.22M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership115.5%51.3%
Insider activity (12mo)21 buy / 28 sell19 buy / 31 sell
Short interest (% of float)9.0%0.1%
Analyst consensus100% buy (1)100% buy (1)
Analyst price target$70 (+41%)$50 (+132%)
StockVane view
StockVane Quant RatingD (24)C (90)
Company
Employees89047,029
Founded19961781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.